Related Experiment Video

Updated: Jun 3, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment

Darren D Browning1, In-Kiu Kwon, Rui Wang

  • 1Department of Biochemistry and Molecular Biology, Medical College of Georgia, 1120 15th Street, CB2516, Augusta, GA 30912, USA. dbrowning@mcg.edu

Future Medicinal Chemistry
|March 24, 2011
PubMed

Insights

cGMP-dependent protein kinases (PKG) show promise as a therapeutic strategy for colon cancer by inhibiting tumor growth and angiogenesis. Further preclinical research is needed to fully explore this potential treatment.

Area of Science:

  • Molecular biology
  • Oncology
  • Biochemistry

Background:

  • cGMP-dependent protein kinases (PKG) are involved in antitumor signaling pathways in colon cancer.
  • The homeostatic and tumor-suppressive effects of cGMP in the intestine are established, but the precise signaling mechanisms require further elucidation.
  • PKG acts as the central effector of cGMP, potentially inhibiting key pathways like β-catenin/TCF and SOX9.

Purpose of the Study:

  • To review the evidence supporting cGMP/protein kinase G (PKG) signaling as a therapeutic strategy for colon cancer.
  • To highlight the role of PKG in blocking colon cancer proliferation and tumor angiogenesis.
  • To underscore the need for additional preclinical studies to validate this therapeutic approach.

Main Methods:

  • Literature review of studies investigating cGMP/PKG signaling in colon cancer.
  • Analysis of molecular mechanisms by which PKG influences cancer cell proliferation and angiogenesis.
  • Evaluation of existing evidence on the therapeutic potential of activating cGMP/PKG pathways.

Main Results:

  • PKG signaling can inhibit colon cancer proliferation by interfering with β-catenin/TCF and SOX9 pathways.
  • PKG activation demonstrates potential in blocking tumor angiogenesis, a critical process in cancer progression.
  • Evidence suggests that therapeutic activation of cGMP/PKG pathways may offer a novel approach to colon cancer treatment.

Conclusions:

  • Therapeutic activation of cGMP/PKG signaling presents a promising strategy for colon cancer prevention and treatment.
  • Understanding the detailed signaling pathways mediated by cGMP/PKG is crucial for optimizing therapeutic interventions.
  • Further preclinical investigations are essential to fully realize the potential of cGMP/PKG-targeted therapies in colon cancer.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...